Translational Research Cancer Centers Consortium Annual Meeting

描述(由申请者提供)：我们正在申请资金，为“翻译区域癌症中心联盟”或TrC3的年度会议提供部分会议支持。TrC3是一个癌症免疫治疗网络，成立的目的是在美国中西部和东北部地区推广生物治疗。在过去的14年里，来自该地区几个癌症中心的实验室和临床研究人员每年都会举行会议，以交流有关各自癌症中心正在进行的研究和新的临床试验的信息。这些中心包括：宾夕法尼亚大学的艾布拉姆森癌症中心、韦恩州立大学的芭芭拉·安·卡马诺斯癌症研究所、病例综合癌症中心、西弗吉尼亚大学的玛丽·巴巴伦道夫癌症中心、俄亥俄州立大学综合癌症中心、宾夕法尼亚州立大学癌症研究所、罗斯威尔公园癌症研究所、匹兹堡大学癌症研究所。这些癌症中心之间的车程在几个小时到半天之内。因此，这次会议为这些群体所在地区的研究人员、医生、其他护理提供者和他们的患者提供了好处。由于生物和免疫治疗的势头正在增强，这次会议是一个重要的、可获得的、负担得起的机会，可以获得有关新的治疗药物、科学发现和临床试验的信息。 这次会议已经成为包括学生、博士后研究员、住院医生和其他医务人员在内的各种学术研究实习生参加正式科学会议、提供数据并与该领域的专家建立有助于职业发展的专业关系的独特经历。这些年度会议于2月的第三周在宾夕法尼亚州七泉市的七泉度假村举行。这个中央会议地点距离大多数成员机构都在合理的车程范围内。NCI的资金将对促进早期规划、确保我们的会议设施、CME信用、有效的广告宣传和保持负担得起的注册率至关重要，以便让受训人员和服务不足的人群有机会参加这次会议。鉴于当前金融环境下机构和公司捐款的不确定性，这一点尤为重要。保护NCI的安全 资金将帮助我们实现TrC3的以下目标：1)为社区中的研究人员和卫生专业人员提供与癌症生物疗法相关的数据的教育机会；2)加强成员机构之间的合作研究和临床试验，使该地理区域内的患者受益。这项工作将由该财团的一组调查人员完成，其中包括首席调查员格雷戈里·莱辛斯基博士(俄亥俄州立大学)和联合调查员伊丽莎白·雷帕斯基博士(RPCI)、帕维尔·卡林斯基博士(UPMC)。这些人中的每个人都曾担任TrC3会议的课程主任，当时会议在各自的机构举行。这些研究人员定期与来自所有成员癌症中心的一组共同组织者沟通并接受指导。 与公共健康相关：使用免疫系统或其他生物疗法抗击癌症的概念正在获得巨大的势头。这次会议将为来自该区域的各种调查人员和受训人员提供一个负担得起的机会，以接受有关该领域最新事态发展的重要教育。此外，它将使人们有机会使用新的有前途的生物制剂开发联合临床试验，这些药物将可用于传统上癌症发病率较高的地理区域的患者。

DESCRIPTION (provided by applicant): We are requesting funds to provide partial meeting support for the annual meetings of the "Translational Regional Cancer Center Consortium" or TrC3. The TrC3 is a cancer immunotherapy network, established to promote biologic therapeutics in the Midwestern and Northeastern regions of the United States. For the past 14 years, laboratory and clinical researches from several of this region's cancer centers have met annually in order to exchange information about the research and new clinical trials underway at their respective cancer centers. These centers include: Abramson Cancer Center at the University of Pennsylvania, Barbara Ann Karmanos Cancer Institute at Wayne State University; Case Comprehensive Cancer Center; Mary Babb Randolph Cancer Center at West Virginia University; The Ohio State University Comprehensive Cancer Center; Penn State Cancer Institute; Roswell Park Cancer Institute; University of Pittsburgh Cancer Institute. These cancer centers are well within a couple of hours to a half day driving distance from one another. Therefore, this meeting provides benefit to researchers, physicians, other care providers and their patients in the areas bounded by these groups. Because biologic and immunologic therapy is gaining momentum, this meeting represents an important, accessible, affordable opportunity to obtain information regarding new therapeutic agents, scientific discoveries and clinical trials. This meeting has become a unique experience for various trainees in academic research including students, post-doctoral fellows, residents and other medical personnel to attend a formal scientific meeting, present data and network with experts in the field to establish professional relationships that will aid career development. These annual meetings are held the third week of February at The Seven Springs Resort in Seven Springs, PA. This central meeting site is within a reasonable driving distance from most member institutions. NCI funds will be essential for facilitating early planning, securing our conference facility, CME credit, effective advertising and maintaining an affordable registration rate to allow for trainees and underserved populations an opportunity to attend this meeting. This is especially important due to the uncertainty of institutional and corporate donations in the current financial climate. Securing NCI funds will help us to achieve the following goals of the TrC3: 1) To provide an educational opportunity for researchers and health professionals in the community on data pertinent to the biologic therapy of cancer; 2) To strengthen collaborative research and clinical trials across member institutions that will benefit patients within this geographic region. This effort will be ld by a group of investigators from the consortium including the Principal Investigator: Dr. Gregory Lesinski (Ohio State), and Co-Investigators: Dr. Elizabeth Repasky (RPCI), Dr. Pawel Kalinski (UPMC). Each of these individuals has served as a Course Director for the TrC3 meeting, when it was held at each respective institution. These investigators communicate regularly with and receive guidance from a group of co-organizers from all member cancer centers. PUBLIC HEALTH RELEVANCE: The concept of using the immune system or other biologic therapies to fight cancer is gaining tremendous momentum. This meeting will provide an affordable opportunity for various investigators and trainees from the region to come together to receive vital education on the most recent developments in this field. Furthermore, it will allow for the opportunity to develop joint clinical trials using new promising biologic agents that will e available to patients in geographic regions with a traditionally high incidence of cancer.